| ||||
clinical trials |
||||
NEWS, PUBLICATIONS, AND RELATED STORIES  Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center.  William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic.   Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related  Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member. Sandra Gendler, Ph.D., was named the David F. and Margaret T. Grohne Research Professor in Therapeutics for Cancer Research. Richard Vile, Ph.D., a consultant in the Department of Molecular Medicine and Department of Immunology at Mayo Clinic Rochester, was honored with The Richard M. Schulze Family Foundation Professorship. Procedure also could prevent recurrence "We show that if you kill tumor cells directly in the tumor itself, you can get a weak immunity against the tumor, but if you use this virus to kill tumor cells in the lymph nodes, you get a higher immunity against the tumor," says Richard Vile, Ph.D., a Mayo Clinic specialist in molecular medicine and immunology and the study's principal investigator. View Abstract   New vaccine for glioblastoma multiforme, an aggressive brain cancer, is now being offered through a clinical trial at Mayo Clinic in Jacksonville. The vaccine represents a fresh and fairly simple approach to treating this cancer, says neurosurgeon Kent New, M.D., Ph.D., who will be leading the study at Mayo. About 40 percent of these tumors display a particular protein on their surface and the vaccine is designed to trick the patient's immune system into thinking the protein is "foreign" in order to mount a killing response. View Related   Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related  The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo  Yuan-Ping Pang, Ph.D. established the Computer-Aided Molecular Design Laboratory (CAMDL) to learn more about how biological systems function and to establish models that could lead to new treatments for infectious diseases and cancer. View Related  Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer. View Related Two major research organizations in the Phoenix area have announced they will collaborate on an ambitious goal: creating a vaccine to prevent the development of cancer. This project is the first initiative undertaken under an umbrella partnership called the Mayo Clinic/ASU Center for Cancer-related Convergence, Cooperation and Collaboration (MAC5). View Related  Double-strand breaks in DNA can result from external agents such as ultraviolet (UV) radiation or mutagenic chemicals. If left unrepaired, a single DNA double-strand break can lead to cell death or cancer. The Mayo research team showed that 53BP1 -- a human protein essential for repairing DNA double-strand breaks -- is recruited to the sites of DNA damage by direct interaction with histone H4, a protein constituent of the DNA packaging structure called chromatin. Findings are published in Dec. 29, 2006, issue of Cell. View Abstract  Findings may help target specific, individualized treatments to patients Certain patients suffering from multiple myeloma, a difficult-to-treat cancer of the plasma cells, may respond positively to a drug that shows potential to extend their survival rates by as much as six months, according to researchers at the Mayo Clinic Cancer Center. For the first time, Mayo researchers have identified tumor-specific alterations in the cellular pathway by which the multiple myeloma drug, bortezomib (Velcade), works, as well as nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent. View Related  Custom-fitting a Drug for a Child with Leukemia Some 20 years ago, Mayo Clinic researcher Richard Weinshilboum, M.D., and colleagues made a groundbreaking discovery: They determined why a dose of a drug that could produce astonishing cures in a lethal childhood cancer sometimes also could produce side effects that killed children. The reason behind this strikingly individual response to a drug was found in the genes. With this profound insight into the role that a patient's genetic make-up plays in how the patient responds to a drug, the new field of pharmacogenomic medicine was born. It continues to grow today—Mayo Clinic research leading the way discovering new treatment applications that range from depression, to breast cancer, to chemical dependency. View Related The collaboration will allow Mayo Clinic and Colorado State to combine expertise in comparative oncology and new treatments for disease. The goal of this collaboration is to bring new diagnostic tests specifically related to cancer and infectious diseases to help us advance biomedical research and bring new diagnostics and therapeutics to patients," says Ronald J. Marler, D.V.M, Ph.D., and associate director for Research/Research Alliances at Mayo Clinic in Arizona. View Related  Mayo Clinic Cancer Center's Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) for prostate cancer research has been renewed for an additional five years. SPORE grants are highly competitive awards given to institutions on the cutting edge of translational research in specific types of cancer. View Related  Seeking a cure for glioblastoma multiforme, other deadly cancers Mayo Clinic is unique in its pursuit of oncolytic measles vaccine strains for cancer treatment, and the research has grown from the most basic laboratory science to the sophisticated therapy being tested today in several tumor types, including glioblastoma multiforme, recurrent ovarian cancer and multiple myeloma. View Related   Mayo Clinic Cancer Center researchers see CDK2/FOXO1 as drug target Mayo Clinic researchers have found that a protein that initiates a "quality control check" during cell division also directs cell death for those cells damaged during duplication. This knowledge represents a potential "bulls eye" for targeting anti-tumor drugs. View Abstract  This annual education event brings cutting-edge research and the clinicians and scientists who study it to those who are interested in women's cancers. View Related Mayo Awarded $72 Million for Clinical and Translational Research "The Mayo Clinic Center for Clinical and Translational Research will coordinate the efforts of our outstanding clinical research education and training programs, our world-class scientists and clinical research investigators, and the vast resources of Mayo Clinic to speed the process of turning our research discoveries into the medications and treatments our patients need and expect," says Robert Rizza, M.D., Mayo Clinic's director for research and the director of the new center. View Related  The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member and recognize distinguished achievement in a specialty area and service to the institution. Faculty are appointed to a professorship through nomination and endorsement of their peers and confirmed by Mayo Clinic senior leadership View Related   Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells. View Related In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental -- and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans. "Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explains Roberto Cattaneo, Ph.D., lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells." View Abstract  "This collaboration will enable us to work with the Indian Health Service to address health care-related needs specific to Native Americans, ranging from developing research initiatives to address unique problems, to finding ways to improve access to medi View Related  Mayo Clinic researchers have shown that the molecule B7-H4 helps renal cell carcinoma (RCC) grow and spread by blocking the immune system. The findings may one day help physicians predict patient outcome and direct treatment, as well as serve as a target at which to aim new and better therapies for this most lethal urologic malignancy. View Abstract In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related  Robert B. Diasio, M.D., has been appointed Mayo Clinic Cancer Center Director, succeeding Franklyn Prendergast, M.D., Ph.D. Dr. Diasio, who will be based at Mayo Clinic in Rochester, will also direct cancer center activities at Mayo Clinic in Arizona and Mayo Clinic in Jacksonville, Fla. View Related The first radiation therapy and respiratory care baccalaureate classes of Mayo School of Health Sciences and the University of Minnesota will be conferred on Friday, May 12, 2006, at Mayo Clinic. View Related  Identifying alterations in DNA methylation may also be useful in determining cancer progression Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression. They also showed that DNA hypermethylation (DNA modification without changing sequence) plays a significant role in these processes. Results of their study were published in the Feb. 15, 2006, issue of Clinical Cancer Research. View Abstract  Renal cell carcinoma is one of most dangerous forms of kidney cancer. An interdisciplinary team of Mayo Clinic investigators and Mayo's Comprehensive Cancer Center are pursuing improved treatments by pooling data and expertise with support from Florida. "With this approach, we can halt the disease and begin to cure kidney cancer." John Copland, M.D. View Related  Mayo Clinic’s Molecular Medicine Program has three gene therapy clinical trials open in which the entire preclinical cycle—concept, discovery of agent, vector manufacture, toxicology and efficacy studies, and new drug application—was conducted at Mayo The projects engineered strains of the measles virus, MV-CEA and MV-NIS, which kill multiple cancer cells, and can be monitored easily. The open trials are in ovarian cancer, glioblastoma multiforme (brain cancer), and multiple myeloma. This article discusses the general research and the first trial which opened -- ovarian cancer. The projects are a fine example of a clear translational effort from bedside to bench and back to the bedside. View Related In terms of a medical diagnosis, nothing is more devastating than hearing the "C" word - cancer. But now, ASU and Mayo Clinic are hoping that five different C's will become the best arsenal against the big C. The organizations have teamed up to introduce a new research entity called MAC5. MAC5 is short for the Mayo Clinic - ASU Center for Cancer-related Convergence, Cooperation and Collaboration. View Related |
Legal restrictions and terms of use applicable to this site
Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.